Home » Market News » DirectorsTalk Highlights » Biotech Companies Investing in Key Technologies for the Fourth Industrial Revolution
Frontier IP Group Plc

Biotech Companies Investing in Key Technologies for the Fourth Industrial Revolution

Technology is constantly impacting and changing the way the world works. Greater technological innovations are not only changing the way business operates, but also have a significant impact on employees.

Over the course of the next five years, the labor market is set to undergo a significant transformation due to those innovations. The World Economic Forum outlined some of the coming changes in its 2018 “The Future of Jobs Report.” The report described those changes as a coming “Fourth Industrial Revolution” that will occur as companies “harness new and emerging technologies to reach higher levels of efficiency of production and consumption.” Some of the new technologies that are considered to be at the forefront of this next revolution include artificial intelligence and machine learning. By 2022, the report showed a number of significant adoptions of technology that industries are likely to make, including big data analytics, mobile applications, machine learning, wearable electronics and more. All of these are areas where the biopharma industry has been making significant investments over the past few years. It was only last week that a report showed wearable technology will be the top fitness trend for the next year. And it’s one area where companies have been able to tap into in order to gain data for personalized medicine and to expand clinical trial data.


Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 30th June 2016, Frontier IP Group Plc (LON:FIPP) have a 5% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.